Key Specifications Table
|Species Reactivity||Key Applications||Host||Format||Antibody Type|
|H||WB, IH(P)||Rb||Unpurified||Polyclonal Antibody|
|Presentation||Rabbit Polyclonal serum with 0.05% sodium azide.|
|Safety Information according to GHS|
|Material Size||50 µL|
|Anti-C9ORF72/C9RANT (poly-GP) -2616199||2616199|
|Anti-C9ORF72/C9RANT (poly-GP) -2685214||2685214|
|Anti-C9ORF72/C9RANT (poly-GP) -2787654||2787654|
|Anti-C9RANT - Q2468270||Q2468270|
|Reference overview||Pub Med ID|
|Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. |
Ash, Peter E A, et al.
Neuron, 77: 639-46 (2013) 2013
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are devastating neurodegenerative disorders with clinical, genetic, and neuropathological overlap. Hexanucleotide (GGGGCC) repeat expansions in a noncoding region of C9ORF72 are the major genetic cause of FTD and ALS (c9FTD/ALS). The RNA structure of GGGGCC repeats renders these transcripts susceptible to an unconventional mechanism of translation-repeat-associated non-ATG (RAN) translation. Antibodies generated against putative GGGGCC repeat RAN-translated peptides (anti-C9RANT) detected high molecular weight, insoluble material in brain homogenates, and neuronal inclusions throughout the CNS of c9FTD/ALS cases. C9RANT immunoreactivity was not found in other neurodegenerative diseases, including CAG repeat disorders, or in peripheral tissues of c9FTD/ALS. The specificity of C9RANT for c9FTD/ALS is a potential biomarker for this most common cause of FTD and ALS. These findings have significant implications for treatment strategies directed at RAN-translated peptides and their aggregation and the RNA structures necessary for their production.